Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer.
Our mission is to develop a new drug to treat Glioblastoma Multiforme.
We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients.
Our mission is to develop a new drug to treat Glioblastoma Multiforme.
We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients.
Location: Norway, Oslo
Employees: 1-10
Total raised: $14.21M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Meneldor | meneldor.n... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.11.2022 | Series A | $3.03M | - |
| 19.10.2022 | - | $9.78M | - |
| 06.05.2022 | Seed | $1.4M | - |
Persons 6
| Date | First Name | Last Name | Title | Location | |||
| - | Adam | Robertson | Chief Scie... | linkedin.c... | - | a*********... | - |
| - | Sandra | Cantilena | Molecular ... | linkedin.c... | - | s*********... | - |
| - | Marek | Cichocki | Director C... | linkedin.c... | - | m*********... | - |
| - | Cecilie S. | Sverdrup | Board Memb... | linkedin.c... | - | i**o@hemis... | - |
| - | Terezia | Prikrylova | Chief Oper... | linkedin.c... | - | t*********... | - |
| - | Zeno | Albisser | Chief Exec... | linkedin.c... | - | z*********... | - |
Mentions in press and media 8
| Date | Title | Description |
| 20.07.2026 | - | TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a c... |
| 08.07.2026 | - | Ovarian cancer remains a major therapeutic challenge, particularly in homologous recombination (HR)-proficient disease where PARP inhibitors (PARPi) presently have limited efficacy, as well as for patients with platinum-resistance. GLIX1 in... |
| 22.05.2026 | - | "We are very pleased to have the opportunity to feature these compelling GLIX1 data during this year's ASCO Annual Meeting," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Our first-in-human Phase 1/2a clinical ... |
| 19.05.2026 | - | GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment. In a comprehensive pre-clinical program, orally administered GLIX1 demonstrated robust anti-t... |
| 28.04.2026 | - | The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center. Northwestern University, led by lead investigato... |
| 24.11.2022 | Hemispherian Raises USD$2.9M in First Tranche of Series A Funding | Hemispherian, an Oslo, Norway-based preclinical pharmaceutical company, raised $2.9M in the first tranche of a Series A funding. The round was led by Meneldor, with participation from Kistefos AS, Kvantia AS, and Steven Powell. The company ... |
| 19.10.2022 | Hemispherian Raises EUR10M in Financing | Hemispherian, an Oslo, Norway-based preclinical pharmaceutical company, raised €10m in financing. The financing included: €2.5M in grant funding €7.5M in equity financing from the European Innovation Council (EIC) Accelerator fund. The comp... |
| 06.05.2022 | Hemispherian Raises USD1.4M in Seed Funding | Hemispherian AS, a Oslo, Norway-based preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, raised NOK 12.5M (USD 1.4M) in seed funding. The round was led by Meneldor, who partne... |